

Supplementary Table S4. Geometric mean (and gCV%) or individual pharmacokinetic parameters of nintedanib, BIBF 1202, and BIBF 1202 glucuronide after multiple oral administration of nintedanib by dose cohort for phase I and phase II

PK parameter (units)	Dose of Nintedanib			
	50 mg bid	100 mg bid	150 mg bid	200 mg bid
	gMean (gCV%)			
	Nintedanib			
C _{max,ss} (nmol/L)	12.9 (12.1) n = 3	38.1 (58.6) n = 7	72.2 (105) n = 6	69.1 (118) n = 17
C _{max,ss,norm} ([nmol/L]/mg)	0.259 (12.1) n = 3	0.381 (58.6) n = 7	0.481 (105) n = 6	0.346 (118) n = 17
t _{max,ss} ^a (h)	1.05 (0.950 to 3.00) n = 3	2.98 (0.917 to 3.97) n = 7	2.03 (1.30 to 4.00) n = 6	2.02 (0 to 10.0) n = 17
t _{1/2,ss} (h)	33.0 (65.2) n = 3	19.7 (35.2) n = 7	18.3 (34.8) n = 6	20.1 (85.5) n = 17
AUC _{0-12,ss} ([nmol•h]/L)	75.0 (17.7) n = 3	228 (53.3) n = 7	390 (67.6) n = 6	390 (103) n = 17
AUC _{0-12,ss,norm} (nmol•h/L/mg)	1.50 (17.7) n = 3	2.28 (53.3) n = 7	2.60 (67.6) n = 6	1.95 (103) n = 17
Ae _{0-12,ss} (μg)	75.5 (46.4) n = 3	212 (99.7) n = 7	357 (48.7) n = 6	348 (108) n = 16
fe _{0-12,ss} (%)	0.151 (46.4) n = 3	0.212 (99.7) n = 7	0.238 (48.7) n = 6	0.185 (108) n = 15
CL _{R,ss} (mL/min)	16.8 (34.1) n = 3	15.5 (57.9) n = 7	15.3 (27.5) n = 6	13.9 (53.7) n = 16
	BIBF 1202			
C _{max,ss,norm} ([nmol/L]/mg)	0.469 (39.8) n = 3	0.565 (142) n = 7	0.578 (117) n = 6	0.713 (219) n = 17
t _{max,ss} ^a (h)	2.00 (0 to 3.00) n = 3	3.98 (1.98 to 5.08) n = 7	2.63 (0 to 5.03) n = 6	2.98 (0 to 11.0) n = 17
AUC _{0-12,ss,norm} (nmol•h/L/mg)	3.97 (43.0) n = 3	4.61 (164) n = 7	4.39 (127) n = 6	5.11 (227) n = 17
	BIBF 1202 glucuronide			
C _{max,ss,norm} ([nmol/L]/mg)	1.51 (159) n = 3	2.99 (176) n = 7	1.87 (71.1) n = 6	3.00 (194) n = 17
t _{max,ss} ^a (h)	3.00 (2.00 to 10.0) n = 3	4.08 (0 to 11.0) n = 7	3.61 (0 to 11.0) n = 6	3.00 (0 to 11.0) n = 17
AUC _{0-12,ss,norm} (nmol•h/L/mg)	15.9 (147) n = 3	31.6 (175) n = 7	20.1 (69.5) n = 6	36.7 (167) n = 16

Abbreviations: $A_{e0-12,ss}$, amount of analyte that is eliminated in urine at steady state over the time interval 0 to 12 hours; $CLR_{,ss}$, renal clearance of the analyte at steady state based on 0–12-hour data; $fe_{0-12,ss}$, fraction of analyte excreted unchanged in urine at steady state over the time interval 0 to 12 hours; gCV, geometric mean of the coefficient of variation; PK, pharmacokinetic.

^aMedian and range